Loading...
Loading...
TAK| Name | Value |
|---|---|
| Revenues | 1,106.7B |
| Cost of Revenue | 384.7B |
| Gross Profit | 722.0B |
| Operating Expense | 537.4B |
| Operating I/L | 184.6B |
| Other Income/Expense | -33.9B |
| Interest Income | 73.8B |
| Pretax | 150.6B |
| Income Tax Expense | 26.4B |
| Net Income/Loss | 124.2B |
Takeda Pharmaceutical Company Limited is a global pharmaceutical company that focuses on research, development, manufacturing, marketing, and out-licensing of pharmaceutical products. The company's product portfolio includes pharmaceuticals in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. It offers a range of branded pharmaceutical products under various well-known brands such as Entyvio, Gattex/Revestive, Takecab, and others. Takeda also engages in collaborations, in-licensing agreements, and strategic alliances with various biotech and pharmaceutical companies to drive innovation and expand its product offerings.
